New York, March 2, 2026, 09:49 EST — Regular session.
- BillionToOne shares fell about 2% to $74.83 in early trading, after finishing Friday at $76.33.
- The diagnostics firm is due to report fourth-quarter and full-year 2025 results after the close on March 4.
- Investors are looking for updates on growth in prenatal and oncology testing and the company’s 2026 outlook.
BillionToOne shares were down about 2% at $74.83 in early trading on Monday. The stock has traded between $73.09 and $74.83 so far in the session, while broader U.S. indexes were also lower. 1
The move comes ahead of the company’s fourth-quarter and full-year 2025 report, due after the market close on Wednesday, March 4, with a conference call scheduled for 4:30 p.m. Eastern. 2
That timing matters because the stock is still finding its footing a few months after its market debut. Traders have been quick to fade rallies in newer healthcare listings this year, especially where visibility on margins and payer coverage is thin.
In January, BillionToOne told investors to expect 2026 revenue of $415 million to $430 million and positive GAAP operating income for the year. Chief executive Dr. Oguzhan Atay said the company had “a clear roadmap” and was focused on “disciplined execution.” 3
BillionToOne priced its IPO at $60 a share in November, selling 4,551,100 shares and targeting gross proceeds of about $273.1 million before fees and expenses, the company said at the time. 4
The Menlo Park, California-based company sells molecular diagnostic tests in prenatal screening and oncology, including non-invasive prenatal screening, or NIPT, and “liquid biopsy,” a blood test designed to spot tumor DNA. 5
For Wednesday’s report, investors will likely focus on test volumes, reimbursement trends and any change in spending plans as the company scales its prenatal portfolio and its Northstar oncology platform. Any revision to the 2026 outlook could set the tone for the rest of the week.
On Wall Street, analysts tracked by MarketBeat show an average price target in the mid-$130s, with targets ranging from about $110 to $160, a sign the stock still sits in a wide debate over growth and valuation. 6
But there is little room for a stumble. If the company’s update points to slower uptake, pricing pressure, or higher costs tied to lab operations and commercial expansion, the stock could stay under pressure.
